TITLE

Diamyd Completes Recruitment In Gene Therapy Pain Trial

AUTHOR(S)
Sheridan, Cormac
PUB. DATE
May 2012
SOURCE
BioWorld International;5/23/2012, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after the implosion of its Type I diabetes immunotherapy program in 2011. The trial is the first placebo-controlled study of the Nerve Targeting Drug Delivery System (NTDDS) technology.
ACCESSION #
77052121

 

Related Articles

  • Diamyd's Shares Tumble on Phase II Gene Therapy Miss. Sheridan, Cormac // BioWorld International;7/5/2012, Vol. 17 Issue 27, p1 

    The article reports on the decline in shares in Diamyd Medical AB following news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial. The study found no difference in average pain scores among patients receiving a single dose of the...

  • Diamyd Medical Reports Results from Phase II Study in Cancer Pain.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that the drug NP2 Enkephalin developed by Diamyd Medical AB did not meet its primary objective of reducing pain in cancer patients. NP2 Enkephalin is based on the Medical's patented Nerve Targeting Drug Delivery System (NTDDS) platform and delivers the natural painkilling...

  • Diamyd's Shares Tumble on Phase II Gene Therapy Miss. Sheridan, Cormac // BioWorld Today;7/5/2012, Vol. 23 Issue 129, p1 

    The article reports that Diamyd Medical AB's gene therapy treatment for cancer pain have missed its primary endpoint in a Phase II placebo-controlled trial. Clinical trials conducted in 18 centers found no difference in average pain scores among patients who received a single dose of the...

  • Clinic Roundup.  // BioWorld Today;5/23/2012, p5 

    This section offers news briefs on clinical trials. A Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron to treat peritumoral brain edema associated with cerebral tumors has been completed by Celtic Pharmaceutical Holdings LP....

  • Biotech ADRs With Near-Term Commercialization Potential. HADDAD, ANTHONY W. // Equities;Oct2009, Vol. 58 Issue 4, p52 

    The article offers information on biotech companies with potential for commercialization whose share prices have doubled for the past 12 months. Starpharma Holdings' lead product VivaGel showed good results in clinical trials and uses nanotechology in preventing the transmission of sexually...

  • Financings Roundup.  // BioWorld Today;4/22/2008, Vol. 19 Issue 78, p4 

    The article reports that a direct placement of 991,000 total series B shares has been executed by Diamyd Medical AB of Stockholm, Sweden. A limited group of professional investors placed the shares at a price of 73 Swedish kronors per share. Proceeds from the share issue would finance the Phase...

  • Diamyd Eyes Spring Start for Phase III Diabetes Trial. Sheridan, Cormac // BioWorld International;2/20/2008, Vol. 13 Issue 8, p2 

    The article reports on the plan by Stockholm, Sweden-based Diamyd Medical AB to begin a Phase III clinical trial of its therapeutic vaccine for Type I diabetes in spring. The U.S. Food and Drug Administration (FDA) questioned a minor aspect of the vaccine's manufacturing process. According to...

  • ADA 2011.  // BioWorld Today;6/29/2011, Vol. 22 Issue 125, p9 

    The article focuses on results presented by Diamyd Medical AB at the 2011 American Diabetes Association meeting from a European trial of its diabetes immunotherapy Diamyd.

  • NIH Trial Of Diabetes Vaccine Boosts Shares Of Diamyd. Sheridan, Cormac // BioWorld International;9/26/2007, Vol. 12 Issue 39, p1 

    The article reports on the increase in the shares of Diamyd Medical AB on news that the National Institute of Diabetes and Digestive and Kidney Diseases is planning to attempt a Phase IIb clinical trial of Diamyd, its therapeutic vaccine for Type I diabetes. The study, under principal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics